BioSpace News Archive

New ‘Trojan horse’ cancer treatment shows early promise in multiple tumour types

A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

February 11, 2019

·

5 min read

Positive T-Track® CMV Study Results With New Guidance Strategies For Anti-viral Treatment Decisions Following Stem Cell Transplantation

Lophius Biosciences GmbH today announced successful top-line results from its multicenter AlloProtect CMV clinical study.

February 11, 2019

·

4 min read

Drug Development

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Data to be presented at the 2019 Genitourinary Cancers Symposium

February 11, 2019

·

15 min read

Drug Development

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo plus low-dose Yervoy continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma.

February 11, 2019

·

35 min read

Drug Development

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer - February 11, 2019

Data to be presented at the 2019 Genitourinary Cancers Symposium

February 11, 2019

·

16 min read

Pharm Country

Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU

First-Time Data from Pivotal Phase 3 KEYNOTE-426 Trial Showing KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Significantly Improved OS, PFS and ORR Compared to Sunitinib Monotherapy in First-Line Treatment of Advanced Renal Cell Carcinoma

February 11, 2019

·

39 min read

Business

Aurora Cannabis Announces Financial Results for the Second Quarter of Fiscal 2019

83% Sequential Net Revenue Growth to $54.2 Million

February 11, 2019

·

20 min read

Deals

Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics announced that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time

February 11, 2019

·

2 min read

Pharm Country

Elizabeth Hillman’s Magic Microscopes: Seeing Inside the Brain

Biomedical Engineer Elizabeth Hillman, PhD, a principal investigator at Columbia’s Mortimer B. Zuckerman Mind Brain Behavior Institute, is inventing new kinds of microscopes that create 3D movies of life in action.

February 11, 2019

·

1 min read

Policy

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

EMD Serono announced that the US Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for BAVENCIO® in combination with INLYTA®* for patients with advanced renal cell carcinoma.

February 11, 2019

·

34 min read